1. Scrip
  2. >>Focus On Asia
  3. >>South Korea

Voronoi In Spotlight For Brain-Permeable Lung Cancer Candidate

Korean Venture Building Platforms, Eyes IPO

 
• By Jung Won Shin

South Korea’s unicorn biotech Voronoi is counting on its novel lung cancer therapy to become a game changer in the market thanks to its high target selectivity and brain permeability.

Digital illustration of lung cancer cells in color background - Illustration
Will Voronoi's NSCLC Drug Candidate Hit A Home Run? • Source: Shutterstock

Voronoi Inc.'s business development team is having the busiest time since its establishment after the South Korean bioventure presented results for its novel non-small cell lung cancer (NSCLC) drug at the recent American Association for Cancer Research (AACR) meeting.

“So many people have gathered at our booth and shown interest to our poster session at the AACR and multiple...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

Bitcoin Player Parataxis To Acquire Bridge Biotherapeutics After IPF Failure

 
• By Jung Won Shin

After the failure of its lead asset in a Phase II trial earlier this year, Korea's Bridge Biotherapeutics has accepted an acquisition offer from bitcoin group Parataxis.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges

MetaVia Sees Obesity Opportunities Despite Challenging US Market

 
• By Jung Won Shin

Despite new challenges related to obesity drug insurance coverage in the US, MetaVia's CEO is confident in the company's novel contender, which unlike rival GLP-1 therapies doesn’t require dose titration.

More from Focus On Asia